You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NTRK

Showing 26 - 50 of 93
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

Recruiting
  • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
  • Shanghai, China
    Shanghai Chest Hospital
Jan 11, 2021

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Solid Tumors Harboring NTRK Fusion Trial in Worldwide (Larotrectinib (Vitrakvi, BAY2757556))

Recruiting
  • Solid Tumors Harboring NTRK Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • Los Angeles, California
  • +50 more
Jan 29, 2023

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting
  • Locally Advanced Solid Tumors
  • +3 more
  • Oral repotrectinib (TPX-0005)
  • Los Angeles, California
  • +27 more
Aug 9, 2022

Solid Tumors Harboring NTRK Fusion Trial in Glendale, Baltimore (Selitrectinib (BAY2731954) Adult tablet, Selitrectinib

Completed
  • Solid Tumors Harboring NTRK Fusion
  • Selitrectinib (BAY2731954) Adult tablet
  • +3 more
  • Glendale, California
  • +1 more
Aug 24, 2021

Solid Tumors Harboring NTRK Fusion Trial in Mannheim (Selitrectinib (BAY2731954))

Completed
  • Solid Tumors Harboring NTRK Fusion
  • Selitrectinib (BAY2731954)
  • Mannheim, Baden-Württemberg, Germany
    CRS Clinical-Research-Services Mannheim GmbH
Dec 28, 2020

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

Solid Tumors Harboring NTRK Fusion Trial in United States (Larotrectinib (Vitrakvi, BAY2757556))

Completed
  • Solid Tumors Harboring NTRK Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • Aurora, Colorado
  • +7 more
May 11, 2021

Tumors Harboring NTRK Fusion Trial (Larotrectinib (Vitrakvi, BAY2757556))

Approved for marketing
  • Tumors Harboring NTRK Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • (no location specified)
Dec 18, 2019

Solid Tumors Harboring NTRK Fusion Trial in Worldwide (BAY2757556 (Larotrectinib, Vitrakvi))

Recruiting
  • Solid Tumors Harboring NTRK Fusion
  • BAY2757556 (Larotrectinib, Vitrakvi)
  • Palo Alto, California
  • +158 more
Aug 8, 2022

Solid Tumors Trial in United States (DS6051b)

Completed
  • Solid Tumors
  • Scottsdale, Arizona
  • +5 more
Sep 18, 2020

Advanced Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +30 more
  • Larotrectinib Sulfate
  • Birmingham, Alabama
  • +123 more
Aug 23, 2022

ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

Terminated
Has Results
  • ALK Fusion Protein Expression
  • +14 more
  • San Francisco, California
    University of California, San Francisco
Jan 14, 2020

Biliary Tract Tumors, Gastric Cancer, Esophageal Squamous Cell Carcinoma Trial in Beijing (FGFR Inhibitor, IDH1 Inhibitor, HER2

Unknown status
  • Biliary Tract Neoplasms
  • +8 more
  • FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
  • Other Therapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Oct 8, 2020

Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

Recruiting
  • Breast Cancer
  • +15 more
  • Goodyear, Arizona
  • +146 more
Aug 24, 2022

Determine the Incidence of NTRK Fusions. NTRK Study

Unknown status
  • Metastatic Solid Tumors
  • Retrospective cohort
  • Bordeaux, Aquitaine, France
    Institut Bergonié
Jul 3, 2019

Solid Tumors, CNS Tumors Trial in Worldwide (Entrectinib)

Recruiting
  • Solid Tumors
  • CNS Tumors
  • Orange, California
  • +38 more
Aug 24, 2022

A Taiwanese Oncogenetic Panel and Integrated Clinical Data

Recruiting
  • Thyroid Cancer
  • A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
  • Kaohsiung, Taiwan
  • +7 more
Sep 12, 2022

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Solid Tumor Trial in United Kingdom, United States (ONO-7579)

Terminated
  • Solid Tumor
  • Lake Success, New York
  • +4 more
Sep 11, 2019

Obesity, Child Trial (sequencing of a panel of 14 genes in leptin melanocortin pathway)

Not yet recruiting
  • Obesity, Child
  • sequencing of a panel of 14 genes in leptin melanocortin pathway
  • (no location specified)
Jul 3, 2023

Cervical/Supraclavicular Metastasis From Non-small-cell Lung

Recruiting
  • Lung Cancer Metastatic
  • Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes
  • Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes
  • Roma, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Jan 23, 2023

NSCLC Trial in United States (Alectinib, Entrectinib, Vemurafenib)

Recruiting
  • Non-small Cell Lung Cancer
  • Duarte, California
  • +24 more
Feb 2, 2023

NSCLC Stage IV, HIV, HBV Trial in Verona (Nivolumab and Ipilimumab)

Not yet recruiting
  • NSCLC Stage IV
  • +4 more
  • Nivolumab and Ipilimumab
  • Verona, Veneto/Verona, Italy
    Centro Ricerche Cliniche
Oct 26, 2022

Thyroid Carcinoma

Recruiting
  • Differentiated Thyroid Carcinoma
  • Medullary Thyroid Carcinoma
  • Immunohistochemistry (IHC)
  • +2 more
  • L'Hospitalet De Llobregat, Barcelona, Spain
  • +11 more
Mar 22, 2022